Trials / Completed
CompletedNCT01336465
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | Repeating subcutaneous injection |
| DRUG | rhuMAb Beta7 | Repeating subcutaneous injection |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-09-01
- Completion
- 2013-06-01
- First posted
- 2011-04-18
- Last updated
- 2016-08-12
Locations
51 sites across 11 countries: United States, Australia, Belgium, Canada, Czechia, Germany, Hungary, Israel, New Zealand, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01336465. Inclusion in this directory is not an endorsement.